Press Releases

GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease

GRAIL today announced a collaboration with global biopharmaceutical companies Amgen, AstraZeneca, and Bristol Myers Squibb to evaluate GRAIL’s methylation-based technology for the detection of minimal residual disease (MRD). Cancer MRD testing is used in clinical and research applications to detect the presence or absence of residual disease. Many MRD tests available today for solid tumors require tissue samples and development of patient-specific assays, which can result in potential delay in treatment decisions. GRAIL’s targeted methylation platform could enable a blood-based MRD detection assay for solid tumors...

GRAIL Confirms Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test

GRAIL has confirmed that it expects to introduce Galleri™, its multi-cancer early detection blood test, in the second quarter of 2021. In December 2020, GRAIL completed the enrollment of PATHFINDER, a prospective, 6,600-participant multi-site interventional study conducted under a U.S. Food and Drug Administration Investigational Device Exemption application to evaluate the implementation of Galleri in clinical practice. PATHFINDER has completed its second planned independent Data and Safety Monitoring Board review. GRAIL expects to present initial results from PATHFINDER, and additional clinical validation from GRAIL’s foundational Circulating Cell-free...

McKesson Ventures Expands Portfolio Development Team and Invests in Market Research

McKesson Ventures has added Lizzie Lee as its newest team member. She joins the firm as senior director, leading its portfolio development and market research efforts. With a decade of healthcare experience, Lee is well-positioned to help McKesson Ventures’ portfolio companies scale by developing and facilitating collaboration amongst the portfolio company, McKesson’s business units, and its customers. Lee will also lead market research efforts to further develop McKesson Ventures’ thought leadership on relevant, emerging trends in the healthcare industry. “I’m passionate about connecting the innovation of novel...

Aspen RxHealth Raises $23M Series B Funding Round Led by Bessemer Venture Partners

Aspen RxHealth, developer of a first-of-its-kind clinical pharmacy model developed by pharmacists for pharmacists that delivers value for health plans and risk-bearing providers, today announced the closure of a $23 million Series B funding round led by Bessemer Venture Partners, with participation from other strategic investors including McKesson Ventures, Novartis, and Takeda Digital Ventures. Previous investors Humana and Flare Capital Partners also participated. The funding will help Aspen RxHealth capitalize on the demand for its highly diverse community of pharmacists and poise the company for successful...

McKesson Launches Ontada, an Oncology Technology and Insights Business Dedicated to Help Advance Cancer Research and Care

McKesson Corporation today announced the launch of Ontada, an oncology technology and insights business designed to support innovation, acceleration, and evidence generation to drive better outcomes for patients with cancer. Building on McKesson’s long history in community oncology, Ontada combines its real-world data and research capabilities with a leading suite of technologies for oncology clinicians, including the iKnowMed℠ electronic health record system and Clear Value Plus℠ regimen support tool, as well as a connection to a national community oncology network to transform the fight against cancer. Ontada’s...

McKesson Ventures Invests as Clinical Ink Debuts Lunexis™ ePRO+ Solution

Clinical Ink, a global clinical trial technology company, today announced an investment from McKesson Ventures, along with its significantly enhanced electronic patient reported outcome (ePRO) module. “McKesson Ventures is excited to invest in Clinical Ink, a market leader in clinical trial enablement technology,” said Dave Schulte, McKesson Ventures senior vice president and managing director. “Clinical Ink’s innovative eSource solutions are particularly well-positioned as the industry shifts to more decentralized trials and remote monitoring.” Lunexis™ ePRO+ is part of a unified technology platform that streamlines implementation processes and...

Michelle Snyder, Digital Health Veteran, Joins McKesson Ventures

McKesson Ventures has hired Michelle Snyder as its newest investment partner. Snyder, a mobile health pioneer, is known for her leadership and guidance in building Epocrates, one of the healthcare industry’s first successful mobile health companies. She brings more than 25 years of healthcare experience to the McKesson Ventures team and will support investments in healthcare technology and services companies. Snyder’s hire also expands the number of female partners at McKesson Ventures, underscoring the firm’s commitment to diversifying its leadership team. Prior to joining McKesson Ventures, Snyder...

Baptist Health Engages Kyruus to Enable Next-Generation Online Patient Access Experience

Kyruus announced that Baptist Health, the largest nonprofit health system in Kentucky, has engaged the company to help elevate its digital access experience for consumers. The health system will collaborate with Kyruus to modernize the care search experience for consumers on the Baptist Health website and enable them to book appointments online. The Baptist Health team re-envisioned the online access experience for consumers, simplifying how they find the right care across the health system’s network and its more than 3,000 employed and affiliated physicians. To achieve...

IVX Health Completes Acquisition of Precision Healthcare

IVX Health, a national provider of infusion and injection therapy for patients with complex chronic conditions such as rheumatoid arthritis, multiple sclerosis, and Crohn’s disease, announced its acquisition of Precision Healthcare. Precision operates 12 infusion centers across Tennessee and northern Arkansas. The acquisition was led by a preferred equity investment from Linden Capital Partners and joined by existing institutional investors McKesson Ventures, Health Velocity Capital, and Nueterra Capital. For more than 20 years, Precision has cared for patients with autoimmune disorders and other conditions. The company employs...

Vineti Extends Series C Funding Round to $68M with an Expanded Investor Coalition

Vineti, a leading digital platform of record for personalized therapeutics, announced the closing of a $33 million extension to its Series C financing round. The new financing will support further expansion of the company’s Personalized Therapy Management (PTM)® platform for personalized and high-value advanced therapies. The Series C extension is led by Cardinal Health, with participation from Marc Benioff and existing Vineti investors including McKesson Ventures, Novartis Pharma AG, LifeForce Capital, Threshold Ventures (formerly DFJ), Section 32, Casdin Capital, and other undisclosed entities. Eli Casdin, chief...